-
Hepa Thera’s HT-101 Secures Breakthrough Therapy Designation from China CDE for Chronic Hepatitis B
Landmark regulatory milestone highlights HT-101’s monotherapy potential to drive HBsAg clearance without immunomodulators.
넶39 2025-07-10
-
Hepa Thera HT-101 Project Summary Meeting Successfully Concludes
On September 28, 2024, the summary meeting for the "Phase I Clinical Study of HT-101 Injection in Healthy Volunteers and Patients with Chronic Hepatitis B Virus Infection," sponsored by Hepa Thera, was successfully held in Beijing.
넶27 2024-09-28
-
Hepa Thera Honored with "VBEF Medical and Health Industry Innovation Product List Top 100"
On May 9, 2024, at the "2024 Future Health 100 Strong Selection" held in Beijing, Hepa Thera was honored with the "VBEF Medical and Health Industry Innovation Product List Top 100".
넶12 2024-05-10
-
Impress at the 3rd Hepatitis Innovation Forum
On March 23rd, the third Hepatitis Innovation Forum, hosted by the China Foundation for Health and Development, took place in Beijing. The forum attracted top experts from basic research, clinical research, and innovative pharmaceutical companies from all over the country to gather and discuss the development trends and challenges in the field of liver disease treatment.
넶15 2024-03-27
-
Hepatitis B Drug HT-101 (siRNA) Receives FDA Clinical Approval
On February 2, 2024, Suzhou Starlight Kunze Biopharmaceutical Co., Ltd. (hereinafter referred to as "Starlight Kunze") announced that its hepatitis B drug candidate HT-101 (siRNA) has received approval from the U.S. FDA to proceed directly to Phase Ib clinical trials for chronic hepatitis B virus infection.
넶18 2024-02-04
-
Hepa Thera Announces First CHB Patient Dosed in HT-101 (Its siRNA Product) Phase 1b Part
This week Suzhou Hepa Thera Biotech Co., Ltd enrolled the first chronic hepatitis B patient in Beijing Friendship Hospital,Capital Medical University for its siRNA product, HT-101. This progress marks HT-101 entering Phase 1b trial, and the trial will be expected to end in the first half year of 2024.
넶23 2023-05-24
-
HT-101 monotherapy with 2 injections achieves surface antigen (HBsAg) seroconversion in 48 weeks! Hepa Thera HT-101 clinical trial makes breakthrough progress!
In the field of hepatitis B treatment, Hepa Thera's HT-101 drug clinical trial has once again brought good news. The latest 48-week follow-up data revealed the drug's significant effect in reducing the levels of hepatitis B surface antigen (HBsAg), especially its astonishing performance at low doses.
넶69 2024-11-08
-
APASL 2025 Live: Hepa Thera Presents New Progress in Functional Cure of Hepatitis B
From March 26th to 30th, 2025, Hepa Thera was invited to participate in the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025 BEIJING).
넶25 2025-04-01
